Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Overindulgence and metabolic syndrome: is FoxO1 a missing link?
Janet D. Sparks, Charles E. Sparks
Janet D. Sparks, Charles E. Sparks
Published May 22, 2008
Citation Information: J Clin Invest. 2008;118(6):2012-2015. https://doi.org/10.1172/JCI35693.
View: Text | PDF
Commentary

Overindulgence and metabolic syndrome: is FoxO1 a missing link?

  • Text
  • PDF
Abstract

Excessive production of triglyceride-rich VLDL, which can result from dietary overindulgence, underlies metabolic syndrome — a combination of disorders including high blood pressure, obesity, high triglyceride, and insulin resistance — and places individuals at increased risk of developing cardiovascular disease and type 2 diabetes. However, the link between VLDL overproduction and insulin resistance has remained unclear. VLDL assembly in the liver is catalyzed by microsomal triglyceride transfer protein (MTP). In this issue of the JCI, Kamagate et al. investigate the events controlling hepatic MTP expression and VLDL production and secretion (see the related article beginning on page 2347). They demonstrate that MTP is a target of the transcription factor FoxO1 and that excessive VLDL production associated with insulin resistance is caused by the inability of insulin to regulate FoxO1 transcriptional activation of MTP.

Authors

Janet D. Sparks, Charles E. Sparks

×

Figure 1

Hepatic VLDL assembly and secretion.

Options: View larger image (or click on image) Download as PowerPoint
Hepatic VLDL assembly and secretion.
FAs, derived from the plasma-free F...
FAs, derived from the plasma-free FA pool, from uptake of circulating lipoproteins (chylomicron remnants), and from de novo hepatic lipogenesis, are esterified via fatty acyl CoA to diacylglyceride (DAG) derivatives and subsequently into TG droplets by diacylglycerol acyl transferase 1 (DGAT1). Lipogenic enzyme expression is regulated by transcription factors including sterol regulatory element binding protein-1c (SREBP-1c) and carbohydrate response element–binding protein (ChREBP), which can be induced in the hyperinsulinemic environment. Mttp gene expression is regulated by FoxO1 as described in the study in this issue of the JCI by Kamagate et al. (7). Insulin acts by binding to its receptor, and activation of the receptor tyrosine kinase, which leads to multiple tyrosine phosphorylation of IRS and subsequent activation of PI3K to produce PIP3. PIP3, in turn, activates phosphoinositide-dependent kinases (PDKs), which phosphorylate and activate Akt, leading to phosphorylation and nuclear exclusion of FoxO1. ER membrane–localized apoB and Mttp mRNAs generate corresponding proteins through translation on ribosomes into the rough ER lumen. Active MTP, in complex with protein disulfide isomerase (PDI), transfers lipids (yellow), including phospholipids, to stabilize nascent apoB during translation, thereby leading to the formation of an emulsion of apoB and lipid in pre-VLDL particles. Cytosolic TG droplets are lipolyzed by TG hydrolases (TGHs), resulting in the release of diacylglyceride and FAs, which are then esterified by DGAT2 to form TG in close association with ER membranes. Pre-VLDL particles fuse with luminal TG droplets, also formed by MTP activity, to form large VLDL particles. Insulin is believed to block VLDL assembly in a post-ER compartment at the fusion stage, possibly through a mechanism involving PI3K-generated PIP3. VLDL particles move through the secretory pathway, where additional remodeling may occur, and are eventually secreted into plasma. Failure of pre-VLDL apoB to attain a proper conformation and to successfully fuse with TG results in the shunting of defective particles (dotted arrow) to autophagolysosomes, the presumptive degradation compartment.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts